System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 6 citations

PubMed: 40186273 DOI: 10.1186/s41479-025-00160-4

Prevention of respiratory syncytial virus disease across the lifespan in Italy.

Pneumonia (Nathan) 17(1):8

Authors: Paolo Manzoni, Eugenio Baraldi, Irene Cetin, Stefania Maggi, Matteo Riccò, Roberta Siliquini, Giovanni Sotgiu, Elsa Viora

Affiliations

  • Department of Public Health and Pediatric Sciences, University of Torino School of Medicine, Torino, 10125, Italy.
  • Department of Maternal-Infant Medicine, "Degli Infermi" Hospital, University of Torino School of Medicine, via dei Ponderanesi, 2, Ponderano, Biella, BI, 13875, Italy.
  • Neonatal Intensive Care Unit, Department of Woman's and Child's Health, University Hospital of Padova, Padova, Italy.
  • Institute of Pediatric Research "Città della Speranza", Padova, Italy.
  • Department of Clinical and Community Sciences, Università degli Studi di Milano, Milano, 20157, Italy.
  • Fondazione IRCCS Ca' Granda, Hospital Maggiore Policlinico, University of Milan, Milano, 20122, Italy.
  • Neuroscience Institute, Aging Branch, National Research Council, Padova, Italy.
  • AUSL-IRCCS di Reggio Emilia, Service for Health and Safety Prevention in the Workplaces (SPSAL), Local Health Unit of Reggio Emilia, Reggio Emilia, Italy.
  • Department of Public Health and Pediatric Sciences, University of Turin, Torino, 10126, Italy.
  • AOU Città Della Salute e Della Scienza, Torino, Italy.
  • Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
  • (Retired) Obstetrics-Gynecological Ultrasound and Prenatal Diagnosis Unit, Department of Obstetrics and Gynecology, AOU Città Della Salute e Della Scienza, Torino, Italy.

Abstract

Respiratory syncytial virus (RSV) causes substantial morbidity and mortality across the lifespan, with the highest burden seen in infants and older adults. Recently approved immunizing agents, including long-acting neutralizing monoclonal antibodies and a maternal vaccine for passive immunization of newborns, and three vaccines for adults aged 60 years and older who are vulnerable to RSV disease, have the potential to prevent severe RSV-associated disease if implemented successfully. The use of these agents will be implemented in some Italian regions over the next few months, although no consistent timelines or decisions for adoption at the national level are expected. A multidisciplinary group of experts in neonatology, obstetrics and gynecology, respiratory medicine, geriatric medicine, hygiene, and public health reviewed the evidence on RSV prevention and present here their considerations on implementing an RSV prevention strategy in Italy. Given the associated disease burden, it is essential to move quickly to deploy these agents in vulnerable populations, enhance surveillance to accurately detect/predict seasonal trends in RSV activity and measure the impact of prevention strategies. Continuing research combined with widespread use of more sensitive testing is needed to identify vulnerable populations and risk factors. Policies are needed to support these preventive measures in the Italian healthcare system, and access must be accompanied by educational initiatives and advocacy to promote acceptance by HCPs and the target population.

MeSH

Respiratory Syncytial Viruses, Vaccines, Viruses, Virus Diseases